Treatment patterns and cost estimations of systemic chemotherapy for pancreatic cancer in Japan: A retrospective database study
Open Access
- 18 May 2023
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 12 (13) , 14742-14755
Abstract
Background: This study aimed to clarify the treatment patterns of pancreatic cancer patients receiving systemic chemotherapy in Japan and to estimate the direct medical costs in actual practice.Research Design and Methods: This retrospective cohort study used electronic health record data between April 2008 and December 2018 in Japan. Participants had a confirmed pancreatic cancer diagnosis and received at least one systemic chemotherapy, including FOLFIRINOX, gemcitabine plus nab‐paclitaxel, gemcitabine, and S‐1. The outcomes were treatment patterns and monthly medical costs and the distribution of monthly medical costs across healthcare resource categories.Results: Of the 4514 selected patients, 40.7%, 7.1%, 24.4%, and 21.3% used gemcitabine plus nab‐paclitaxel, FOLFIRINOX, gemcitabine, and S‐1 as first‐line chemotherapy, respectively. The median monthly medical costs were the highest in the first month, with gemcitabine plus nab‐paclitaxel ranking first (6813 USD), followed by FOLFIRINOX, gemcitabine, and S‐1. The health resource categories with the highest shares of monthly medical costs during the first‐line treatment period with gemcitabine plus nab‐paclitaxel and FOLFIRINOX were hospitalization costs (FOLFIRINOX: 41%–37%; gemcitabine plus nab‐paclitaxel: 40%–34%) and medicine costs (FOLFIRINOX: 51%–42%; gemcitabine plus nab‐paclitaxel: 49%–38%).Conclusions: This study sheds light on the current treatment patterns and direct medical costs of systemic chemotherapy for pancreatic cancer in Japan.Keywords
Funding Information
- Japan Society for the Promotion of Science (19H03874)
This publication has 16 references indexed in Scilit:
- Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)The Lancet, 2016
- Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancerCancer Chemotherapy and Pharmacology, 2016
- Prospective study of cetuximab and gemcitabine in combination with radiation therapy: feasibility and efficacy in locally advanced pancreatic head cancerRadiation Oncology, 2015
- Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) projectJapanese Journal of Clinical Oncology, 2015
- Phase II study of FOLFIRINOX for chemotherapy‐naïve Japanese patients with metastatic pancreatic cancerCancer Science, 2014
- Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysisBMC Cancer, 2014
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST StudyJournal of Clinical Oncology, 2013
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic CancerJournal of Clinical Oncology, 2007